Passage BIO PASG
NASDAQ PASG
$4.32 -0.18 (-4.11%)
As of: Oct 1, 2026 · 3:59 PM EDT

Passage BIO (PASG) Liabilities and Shareholders Equity (2019 - 2026)

Updated

Passage BIO (PASG) posted Liabilities and Shareholders Equity of $25.18 million for Q2 2026, down 68.2% from $79.2 million a year earlier and down 31.0% from the prior quarter.

Analysis

Passage BIO (PASG) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

At the end of FY2025, Passage BIO's Liabilities and Shareholders Equity came in at $62.28 million, down 39.2% from FY2024.

  • Annual Liabilities and Shareholders Equity has declined for four consecutive years, with a five-year compound annual growth rate of -28.3% (FY2020 to FY2025).
  • In prior years, Passage BIO's Liabilities and Shareholders Equity was $102.41 million in FY2024 (-32.0%), $150.55 million in FY2023 (-38.2%), $243.55 million in FY2022 (-31.4%) and $355.08 million in FY2021 (+8.3%).
  • The Q2 2026 figure stands as the lowest quarterly Liabilities and Shareholders Equity in data going back to Q4 2019.
  • On a year-over-year basis, Liabilities and Shareholders Equity has declined in each of the last 18 quarters, with an average decline of 42.5% over the last eight quarters.
  • The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q3 2021, with growth of 9.0%; the weakest was Q2 2026, with a decline of 68.2%.
  • According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $36.46 million (Q1 2026), $62.28 million (Q4 2025) and $74.16 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Passage BIO 14.48 Mn 14.48 Mn - 25.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.18 Mn
Mar 31, 2026 36.46 Mn
Dec 31, 2025 62.28 Mn
Sep 30, 2025 74.16 Mn
Jun 30, 2025 79.20 Mn
Mar 31, 2025 86.01 Mn
Dec 31, 2024 102.41 Mn
Sep 30, 2024 111.75 Mn
Jun 30, 2024 125.39 Mn
Mar 31, 2024 140.53 Mn
Dec 31, 2023 150.55 Mn
Sep 30, 2023 169.26 Mn
Jun 30, 2023 193.70 Mn
Mar 31, 2023 213.24 Mn
Dec 31, 2022 243.55 Mn
Sep 30, 2022 270.05 Mn
Jun 30, 2022 299.42 Mn
Mar 31, 2022 333.22 Mn
Dec 31, 2021 355.08 Mn
Sep 30, 2021 390.94 Mn
API Access

Passage BIO Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=PASG&period=max&api_key=YOUR_API_KEY